|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CASZ1 |
Gene summary for CASZ1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CASZ1 | Gene ID | 54897 |
| Gene name | castor zinc finger 1 | |
| Gene Alias | CAS11 | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B3KRV8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54897 | CASZ1 | CCI_1 | Human | Cervix | CC | 4.93e-05 | 6.29e-01 | 0.528 |
| 54897 | CASZ1 | CCI_2 | Human | Cervix | CC | 5.09e-04 | 8.21e-01 | 0.5249 |
| 54897 | CASZ1 | CCI_3 | Human | Cervix | CC | 1.78e-09 | 7.41e-01 | 0.516 |
| 54897 | CASZ1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.75e-04 | -2.24e-01 | 0.0155 |
| 54897 | CASZ1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.54e-02 | 4.57e-01 | -0.1464 |
| 54897 | CASZ1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.23e-14 | -5.06e-01 | 0.294 |
| 54897 | CASZ1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.06e-03 | -2.68e-01 | 0.3005 |
| 54897 | CASZ1 | A002-C-010 | Human | Colorectum | FAP | 1.28e-07 | -2.84e-01 | 0.242 |
| 54897 | CASZ1 | A015-C-203 | Human | Colorectum | FAP | 4.67e-28 | -3.76e-01 | -0.1294 |
| 54897 | CASZ1 | A015-C-204 | Human | Colorectum | FAP | 1.68e-07 | -2.32e-01 | -0.0228 |
| 54897 | CASZ1 | A014-C-040 | Human | Colorectum | FAP | 1.20e-05 | -4.22e-01 | -0.1184 |
| 54897 | CASZ1 | A002-C-201 | Human | Colorectum | FAP | 4.11e-15 | -2.32e-01 | 0.0324 |
| 54897 | CASZ1 | A002-C-203 | Human | Colorectum | FAP | 1.33e-04 | -1.45e-01 | 0.2786 |
| 54897 | CASZ1 | A001-C-119 | Human | Colorectum | FAP | 1.99e-05 | -4.16e-02 | -0.1557 |
| 54897 | CASZ1 | A001-C-108 | Human | Colorectum | FAP | 1.46e-12 | -1.87e-01 | -0.0272 |
| 54897 | CASZ1 | A002-C-205 | Human | Colorectum | FAP | 9.27e-23 | -3.26e-01 | -0.1236 |
| 54897 | CASZ1 | A015-C-005 | Human | Colorectum | FAP | 1.53e-03 | -4.22e-02 | -0.0336 |
| 54897 | CASZ1 | A015-C-006 | Human | Colorectum | FAP | 2.51e-16 | -2.54e-01 | -0.0994 |
| 54897 | CASZ1 | A015-C-106 | Human | Colorectum | FAP | 2.72e-13 | -2.56e-01 | -0.0511 |
| 54897 | CASZ1 | A002-C-114 | Human | Colorectum | FAP | 2.92e-20 | -3.06e-01 | -0.1561 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CASZ1 | SNV | Missense_Mutation | novel | c.4016C>T | p.Ser1339Phe | p.S1339F | Q86V15 | protein_coding | deleterious_low_confidence(0) | benign(0.421) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| CASZ1 | SNV | Missense_Mutation | novel | c.2621C>T | p.Ser874Leu | p.S874L | Q86V15 | protein_coding | tolerated_low_confidence(0.14) | possibly_damaging(0.68) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| CASZ1 | SNV | Missense_Mutation | c.1114C>T | p.Arg372Cys | p.R372C | Q86V15 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CASZ1 | SNV | Missense_Mutation | c.1306G>T | p.Asp436Tyr | p.D436Y | Q86V15 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CASZ1 | SNV | Missense_Mutation | c.1946N>G | p.Tyr649Cys | p.Y649C | Q86V15 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BH-A0C1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CASZ1 | SNV | Missense_Mutation | rs761954486 | c.2099C>T | p.Ser700Leu | p.S700L | Q86V15 | protein_coding | tolerated(0.18) | probably_damaging(0.988) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CASZ1 | SNV | Missense_Mutation | c.3032G>A | p.Arg1011His | p.R1011H | Q86V15 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-E9-A228-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CASZ1 | SNV | Missense_Mutation | novel | c.1029N>A | p.Asn343Lys | p.N343K | Q86V15 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| CASZ1 | deletion | Frame_Shift_Del | c.1831delC | p.His611ThrfsTer75 | p.H611Tfs*75 | Q86V15 | protein_coding | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| CASZ1 | insertion | In_Frame_Ins | novel | c.2787_2788insCCC | p.Arg929_Ser930insPro | p.R929_S930insP | Q86V15 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |